Summary. The secretion of somatostatin and glucagon by the perfused rat pancreatico-duodenal preparation was examined in situ under control conditions and after the induction of acute insulin deficiency by alloxan or streptozotocin. A 10min 0.625 mmol/1 alloxan perfusion resulted in an immediate and transient increase in basal insulin and glucagon release and a slightly delayed and persistent increase in basal somatostatin secretion. The insulin responses to 16.7mmol/I glucose, 1 mmol/1 theophylline, and 19 mmol/l arginine alone or.in combination were virtually eliminated by atloxan treatment. Somatostatin secretion in response to the stimuli was completely inhibited or markedly attenuated. The glucagon-suppressive effect of glucose was unaltered by alloxan and the stimulatory effect of arginine was enhanced. Addition of 1 ~xg/ml porcine insulin to the perfusion medium did not modify the alterations in somatostatin and glucagon responses to arginine. Streptozotocin treatment 90 rain prior to the onset of perfusion resulted in changes in somatostatin, glucagon, and insulin responses to glucose and arginine similar to those of alloxan. The present results are consistent with an effect of alloxan and streptozotocin on the D cell similar to that on the B cell, namely, interference with a glucose-mediated effect on hormone secretion.
Somatostatin is localized within the pancreas in secretory granules in D cells of the islets of Langerhans [1, 2] and its secretion is enhanced by glucose [3, 4] , theophylline [5, 6] , and glucagon [7] . Administration of exogenous somatostatin inhibits the release of insulin and glucagon [8, 9] . These observations, together with those of D cell hyperplasia and hypertrophy and of increased pancreatic somatostatin-like immunoreactivity in streptozotocin-and alloxaninduced diabetes in the rat [10] [11] [12] and in human insulin-dependent diabetes [13] , suggest that somatostatin exhibits an important role in the physiology of islet function and possibly in the pathophys.-iology of diabetes.
It has recently been reported that plasma somatostatin-like immunoreactivity is elevated in alloxan diabetic dogs [14] and in streptozotocin diabetic rats [15] and that somatostatin secretion from the isolated perfused pancreas of alloxan diabetic rats is exaggerated in response to arginine [16] . In another study, by contrast, normal pancreatic somatostatin responses to arginine, isoproterenol and calcium and a diminished response to glucose were seen in streptozotocin diabetic dogs [17] . The present study was therefore undertaken to investigate further the acute effects of alloxan and streptozotocin on pancreatic somatostatin secretion in the isolated perfused rat pancreas.
Materials and Methods
Pancreases and attached segments of duodenum from overnight fasted male Sprague Dawley rats weighing 300-350 g, were perfused in situ by a previously described method [6] . All perfusions were. performed in pairs consisting of one experimental and one control animal. Perfusion medium consisted of Krebs-Ringer bicarbonate (KRB) buffer containing 0.25 g/100 ml bovine serum albumin and 4.6g/100ml dextran (mean molecular weight 70,000). The medium was gassed with 95% O z -5% CO~. and maintained at pH 7.4 and PaO 2 350 mm Hg. The flow rate was maintained constant at 2 ml/min and test materials were introduced through a side arm to provide the desired concentrations.
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Under the perfusion conditions, a 3-4 rain interval was required for newly introduced medium or test materials to reach the pancreas. After a 20 min equilibration perfusion with 1.4 mmol/l glucose, the following experiments were performed.
Experiment I
Alloxan monohydrochloride (0.625 mmol/l) was perfused for 10 min after which the pancreas was perfused with 16.7 mmol/l glucose for 30rain, followed by 19mmol/l arginine and 16.7 mmol/t glucose for 20 rain. As a control for this experiment, perfusions were performed without the initial aUoxan treatment.
Experiment H
Alloxan monohydrochloride (0.625mmol/1) was perfused for 10 min after which the pancreas was perfused with t6.7 mmol/l glucose for 15rain, followed by 1 mmot/1 theophylline plus 16.7 mmol/l glucose for 20 min and 19 mmol/l arginine, 1 mmol/l theophylline, and 16.7 mmol/1 glucose for 20 rain. As a control for this experiment, perfusions were performed without prior alloxan treatment,
Experiment III
The protocol of this experiment was identical to that of experiment II, with the exception that porcine insulin (1 p.g/ml) was added during the 16.7 mmol/l glucose perfusion. Control perfusions were performed without the addition of insulin.
Experiment IV
In this experiment streptozotocin (I 00 mg/kg), dissolved in citrate buffered saline pH 4-.0, was injected intravenously seventy minutes before starting the perfusion. After a 20 rain equilibration perfusion with 1.4.retool/1 glucose, the pancreases w.ere perfused with 16.7 mmol/1 glucose for 30 rain, followed by 19 mmol/1 arginine plus 16.7 mmol/I glucose for 20 min. Control experiments were performed using pancreases from the rats injected with saline. The effluent from the portal vein was collected at the times indicated in the figures into chilled tubes containing a bacitracinaprotinin mixture (2 x 10-Smol/I and 1000KIU/ml, respectively), and stored at -20 ~ until assay.
Immunoreactive somatostatin was determined by a previously described procedure [18] . The assay sensitivity was 15 pg/ml and serial dilutions of perfusate somatostatin immunoreactivity were parallel to those of synthetic somatostatin. The mean recovery of somatostatin added to the perfusate was 82%. Immunoreactive insulin was determined as previously described [19] , using rat insulin as standard. Immunoreactive glucagon was measured as previously described [19] using antiserum 30 K. The sensitivities of the insulin and glucagon assays were 0.1 ng/ml and 20 pg/ml, respectively. Statistical differences were determined by a two factor analysis of variance.
Results
The Effect of Alloxan on Insulin, Ghtcagon, and Somatostatin Secretion in Response to Glucose and Arginine (Fig. 1) The infusion of alloxan caused a transient increase in insulin secretion followed by complete inhibition of the insulin response to 16.7 mmol/1 glucose and to arginine plus glucose. Glucagon secretion was also transiently increased by alloxan (perfusion period 5-8 rain: F = 30.9, P < 0.001 vs control), though the drug did not impair the ability of 16.7 mmol/1 glucose to suppress glucagon secretion to undectectable levels (< 20 pg/ml). The arginine-induced glucagon response in the presence of 16.7 mmol/l glucose was significantly greater (P < 0.001) in the alloxan pretreatment group than in controls.
Somatostatin secretion was not acutely altered by aUoxan. However, upon removal of alloxan from the perfusion medium, somatostatin secretion increased to about twice basal levels (perfusion period 10-14 min: F = 9.29, P < 0.005 vs control) and did not respond further to 16,7 mmol/t glucose stimulation (F = 107, P < 0.001 vs control). The somatostatin levels achieved during the last 10 rnin of peffusion with 16.7 retool/1 glucose were 67% greater in controls than in alloxan-treated pancreases (F = 18.2, P < 0.001). In response to arginine plus glucose, a slight stimulation was observed though the response was markedly reduced when compared to that of controls (P < 0.001). (Fig. 2) Insulin, glucagon, and somatostatin secretion in response to alloxan and to 16.7 mrnol/l glucose in this experiment were comparable to that in Figure 1 . Alloxan pretreatment completely (> 99%), inhibited the insulin response to theophylline and to arginine. Alloxan pretreatment did not alter the tack of glucagon response to theophylline observed in the controls but the ~ucagon response to arginine plus theophylline was significantly increased (F = 21.9, P < 0.001 vs controls). Somatostatin secretion was stimulated by theophylline in control peffusions but not in alloxan peffusions. Both groups responded to stimulation by arginine plus theophytline but the somatostatin response was markedly attenuated in the alloxan group (F = ti3.9, P < 0.001). (Fig. 3) The effect of correcting the acute insulin deficiency which followed alloxan treatment was assessed by l infusing porcine insulin at a concentration of i btg/ml ; during the 16.7 mmoI/l glucose and the glucose plus arginine perfusion. The glucagon and somatostatin responses to the two stimuli were indistinguishable from those in the absence of insulin: the glucagon response to arginine remained increased and the somatostatin responses to glucose and to arginine remained absent or markedly suppressed. (Fig. 4) Insulin secretion in response to glucose and to arginine plus glucose perfusion was markedly reduced after the intravenous injection of streptozotocin. The suppression of glucagon secretion by glucose was not modified by streptozotocin, while the glucagon response to arginine plus glucose was significantly greater after streptozotocin treatment (P < 0.001). The somatostatin responses to glucose (F = 62.9, P < 0.001) and to arginine plus glucose (P < 0.001) were significantly reduced by streptozotocin treatment.
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Discussion
The present studies were designed to examine the acute effects of alloxan and streptozotocin on the secretion of somatostatin by the isolated perfused rat pancreatico-duodenal preparation and to compare these responses with those on insulin and glucagon. While these experiments cannot differentiate between a pancreatic or duodenal origin of the released somatostatin, experience in the dog suggests that the duodenal component is not significant [20] .
Perfusion with alloxan caused an immediate release of insulin with a subsequent loss of insulin responses to glucose alone or glucose plus arginine and/or theophylline, as has previously been documented [21] [22] [23] . Glucagon secretion also increased acutely during alloxan perfusion. Following altoxan the inhibition of glucagon release in response to glucose alone or with theophylline was unchanged, while the response to arginine was exaggerated as previously reported in one similar study [23] but not another utilizing a more chronic preparation [17] . This discrepancy may be explained by the more complete metabolic abnormality seen in long term studies. Somatostatin release did not respond abruptly to the onset of the alloxan infusion but rather increased slowly during a five minute period following discontinuation of aUoxan. This rise may represent an elevation in basal secretion due to the effect of alloxan, possibly explaining the increased somatostatin release seen in animals with diabetes following alloxan ] 14, 16] . An alternate explanation is that the elevation in somatostatin seen soon after atloxan merely represents a more rapid response to elevated glucose. This is less likely, however, as the overall response to 16.7 mmol/1 glucose was decreased. While somatostatin secretion was increased by glucose plus arginine and, more markedly, in the presence of theophylline, these responses were considerably decreased from those in controls.
It has been suggested that endogenous insulin, gtucagon and somatostatin act locally within the islet to regulate each others' secretion. If this is correct, it could be argued that the toxic effect of alloxan on insulin secretion removes one regulatory factor from this interaction causing the exaggeration of glucagon release and the decrease of somatostatin release seen in response to arginine and glucose. The failure of insulin infusion after alloxan treatment to influence these responses confirms the data of Hermansen et al. [17] and is evidence against this possibility. The use of heterologous insulin in this experiment cannot explain our result in as much as porcine insulin is fully active in the rat. Alternately, it is conceivable that the B, A and D cells of the pancreatic islets are merely affected differently by alloxan resulting in three different patterns of secretory response which do not reflect a failure of internal regulation.
Streptozotocin treatment resulted in similar changes in insulin and glucagon secretion to those seen following alloxan. Somatostatin secretion following streptozotocin again showed parallelism to that of insulin with a poor response to glucose stimulation alone, or with arginine. Previous studies [t5, 17] have shown that arginine elicited a normal somatostatin response following streptozotocin. This discrepancy may be accounted for by differences in the time of study after streptozotocin administration. The acute secretory responses to streptozotocin could not be evaluated since the drug was given prior to initiating the perfusion and basal somatostatin secretion was unaltered.
It is of interest to note that the secretion of insulin and somatostatin, normally stimulated by glucose, is decreased following alloxan or streptozotocin and conversely that the secretion of glucagon, normally inhibited by glucose is hyperresponsive following alloxan or streptozotocin. These results suggest that a major effect of these islet cell toxins in mediated by the glucose receptor mechanism.
In conclusion, the present results demonstrate an increase in basal somatostatin secretion in response to alloxan and an impairment in the somatostatin response to glucose, theophylline, and arginine after alloxan or streptozotocin administration. The relationship of these acute effects to islet cell toxins and the persistent increase in somatostatin secretion observed chronically after treatment with these agents will require further study.
